We investigated the influence of membrane cholesterol content on preferential and non-preferential signaling through the M(2) muscarinic acetylcholine receptor expressed in CHO cells. Cholesterol depletion by 39% significantly decreased the affinity of M(2) receptors for [(3)H]-N-methylscopolamine ([(3)H]-NMS) binding and increased B(max) in intact cells and membranes. Membranes displayed two-affinity agonist binding sites for carbachol and cholesterol depletion doubled the fraction of high-affinity binding sites. In intact cells it also reduced the rate of agonist-induced receptor internalization and changed the profile of agonist binding from a single site to two affinity states. Cholesterol enrichment by 137% had no effects on carbachol E(max) of cAMP synthesis inhibition and on cAMP synthesis stimulation and inositolphosphates (IP) accumulation at higher agonist concentrations (non-preferred pathways). On the other hand, cholesterol depletion significantly increased E(max) of cAMP synthesis inhibition or stimulation without change in potency, and decreased E(max) of IP accumulation. Noteworthy, modifications of membrane cholesterol had no effect on membrane permeability, oxidative activity, protein content, or relative expression of G(s), G(i/o), and G(q/11) alpha subunits. These results demonstrate distinct changes of M(2) receptor signaling through both preferential and non-preferential G-proteins consequent to membrane cholesterol depletion that occur at the level of receptor/G-protein/effector protein interactions in the cell membrane. The significant decrease of IP accumulation by cholesterol depletion was also observed in cells expressing M(3) receptors and by both cholesterol depletion and enrichment in cells expressing M(1) receptors indicating relevance of reduced G(q/11) signaling for the pathogenesis of Alzheimer's disease.

Institute of Physiology CAS Prague Czech Republic

Zobrazit více v PubMed

Abad-Rodriguez J, Ledesma MD, Craessaerts K, Perga S, Medina M, Delacourte A, Dingwall C, De Strooper B, Dotti CG. Neuronal membrane cholesterol loss enhances amyloid peptide generation. J Cell Biol. 2004;167:953–960. PubMed PMC

Abdulaev NG, Ngo T, Ramon E, Brabazon DM, Marino JP, Ridge KD. The receptor-bound „empty pocket“ state of the heterotrimeric G-protein alpha-subunit is conformationally dynamic. Biochemistry. 2006;45:12986–12997. PubMed

Azpiazu I, Gautam N. A fluorescence resonance energy transfer-based sensor indicates that receptor access to a G protein is unrestricted in a living mammalian cell. J Biol Chem. 2004;279:27709–27718. PubMed

Baker JG, Hill SJ. Multiple GPCR conformations and signalling pathways: implications for antagonist affinity estimates. Trends Pharmacol Sci. 2007;28:374–381. PubMed PMC

Bonner TI. The molecular basis of muscarinic receptor diversity. Trends Neurosci. 1989;12:148–151. PubMed

Buxbaum JD, Oishi M, Chen HI, Pinkas-Kramarski R, Jaffe EA, Gandy SE, Greengard P. Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. Proc Natl Acad Sci U S A. 1992;89:10075–10078. PubMed PMC

Caulfield MP, Birdsall NJ. International Union of Pharmacology. XVII Classification of muscarinic acetylcholine receptors. Pharmacol Rev. 1998;50:279–290. PubMed

Colozo AT, Park PS, Sum CS, Pisterzi LF, Wells JW. Cholesterol as a determinant of cooperativity in the M2 muscarinic cholinergic receptor. Biochem Pharmacol. 2007;74:236–255. PubMed

Doležal V, Tuček S. The effects of brucine and alcuronium on the inhibition of [3H]-acetylcholine release from rat striatum by muscarinic receptor agonists. Br J Pharmacol. 1998;124:1213–1218. PubMed PMC

Escriba PV, Wedegaertner PB, Goni FM, Vogler O. Lipid-protein interactions in GPCR-associated signaling. Biochim Biophys Acta. 2007;1768:836–852. PubMed

Flynn DD, Ferrari-DiLeo G, Mash DC, Levey AI. Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer‘s disease. J Neurochem. 1995;64:1888–1891. PubMed

Fredriksson R, Lagerstrom MC, Lundin LG, Schioth HB. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol. 2003;63:1256–1272. PubMed

Grimm MO, Grimm HS, Patzold AJ, Zinser EG, Halonen R, Duering M, Tschape JA, De Strooper B, Muller U, Shen J, Hartmann T. Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat Cell Biol. 2005;7:1118–1123. PubMed

Grimm MO, Grimm HS, Tomic I, Beyreuther K, Hartmann T, Bergmann C. Independent inhibition of Alzheimer‘s disease beta - and gamma-secretase cleavage by lowered cholesterol levels. J Biol Chem. 2008;283:11302–11311. PubMed

Haigh LS, Leatherman GF, O‘Hara DS, Smith TW, Galper JB. Effects of low density lipoproteins and mevinolin on cholesterol content and muscarinic cholinergic responsiveness in cultured chick atrial cells. Regulation of levels of muscarinic receptors and guanine nucleotide regulatory proteins. J Biol Chem. 1988;263:15608–15618. PubMed

Hartmann T, Kuchenbecker J, Grimm MO. Alzheimer‘s disease: the lipid connection. J Neurochem. 2007;103(Suppl 1):159–170. PubMed

Hornigold DC, Mistry R, Raymond PD, Blank JL, Challiss RA. Evidence for cross-talk between M2 and M3 muscarinic acetylcholine receptors in the regulation of second messenger and extracellular signal-regulated kinase signalling pathways in Chinese hamster ovary cells. Br J Pharmacol. 2003;138:1340–1350. PubMed PMC

Hulme EC, Birdsall NJ, Buckley NJ. Muscarinic receptor subtypes. Annu Rev Pharmacol Toxicol. 1990;30:633–673. PubMed

Jakubík J, Bacakova L, El-Fakahany EE, Tuček S. Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol. 1997;52:172–179. PubMed

Jakubík J, Bacakova L, el-Fakahany EE, Tuček S. Subtype selectivity of the positive allosteric action of alcuronium at cloned M1-M5 muscarinic acetylcholine receptors. J Pharmacol Exp Ther. 1995;274:1077–1083. PubMed

Jakubík J, El-Fakahany EE, Doležal V. Differences in kinetics of xanomeline binding and selectivity of activation of g proteins at m1 and m2 muscarinic acetylcholine receptors. Mol Pharmacol. 2006;70:656–666. PubMed

Jakubík J, Tuček S, El-Fakahany EE. Allosteric modulation by persistent binding of xanomeline of the interaction of competitive ligands with the M1 muscarinic acetylcholine receptor. J Pharmacol Exp Ther. 2002;301:1033–1041. PubMed

Kenakin T. Ligand-selective receptor conformations revisited: the promise and the problem. Trends Pharmacol Sci. 2003;24:346–354. PubMed

Klein U, Gimpl G, Fahrenholz F. Alteration of the myometrial plasma membrane cholesterol content with beta-cyclodextrin modulates the binding affinity of the oxytocin receptor. Biochemistry. 1995;34:13784–13793. PubMed

Kobilka BK. G protein coupled receptor structure and activation. Biochim Biophys Acta. 2007;1768:794–807. PubMed PMC

Krejčí A, Tuček S. Quantitation of mRNAs for M(1) to M(5) subtypes of muscarinic receptors in rat heart and brain cortex. Mol Pharmacol. 2002;61:1267–1272. PubMed

Lazareno S, Birdsall NJ. Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. Mol Pharmacol. 1995;48:362–378. PubMed

Lazareno S, Doležal V, Popham A, Birdsall NJ. Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity. Mol Pharmacol. 2004;65:257–266. PubMed

Ledesma MD, Abad-Rodriguez J, Galvan C, Biondi E, Navarro P, Delacourte A, Dingwall C, Dotti CG. Raft disorganization leads to reduced plasmin activity in Alzheimer‘s disease brains. EMBO Rep. 2003;4:1190–1196. PubMed PMC

Machová E, Jakubík J, Michal P, Oksman M, Iivonen H, Tanila H, Doležal V. Impairment of muscarinic transmission in transgenic APPswe/PS1dE9 mice. Neurobiol Aging. 2008;29:368–378. PubMed

Michal P, El-Fakahany EE, Doležal V. Muscarinic M2 receptors directly activate Gq/11 and Gs G-proteins. J Pharmacol Exp Ther. 2007;320:607–614. PubMed

Michal P, Lysíková M, Tuček S. Dual effects of muscarinic M(2) acetylcholine receptors on the synthesis of cyclic AMP in CHO cells: dependence on time, receptor density and receptor agonists. Br J Pharmacol. 2001;132:1217–1228. PubMed PMC

Migeon JC, Nathanson NM. Differential regulation of cAMP-mediated gene transcription by m1 and m4 muscarinic acetylcholine receptors. Preferential coupling of m4 receptors to Gi alpha-2. J Biol Chem. 1994;269:9767–9773. PubMed

Mistry R, Dowling MR, Challiss RA. An investigation of whether agonist-selective receptor conformations occur with respect to M2 and M4 muscarinic acetylcholine receptor signalling via Gi/o and Gs proteins. Br J Pharmacol. 2005;144:566–575. PubMed PMC

Mitchell DC, Straume M, Miller JL, Litman BJ. Modulation of metarhodopsin formation by cholesterol-induced ordering of bilayer lipids. Biochemistry. 1990;29:9143–9149. PubMed

Nitsch RM, Slack BE, Wurtman RJ, Growdon JH. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science. 1992;258:304–307. PubMed

Nováková J, Mikasová L, Machová E, Lisá V, Doležal V. Chronic treatment with amyloid beta(1–42) inhibits non-cholinergic high-affinity choline transport in NG108-15 cells through protein kinase C signaling. Brain Res. 2005;1062:101–110. PubMed

Peterson GL. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem. 1977;83:346–356. PubMed

Pike LJ. Lipid rafts: bringing order to chaos. J Lipid Res. 2003;44:655–667. PubMed

Renaud JF, Scanu AM, Kazazoglou T, Lombet A, Romey G, Lazdunski M. Normal serum and lipoprotein-deficient serum give different expressions of excitability, corresponding to different stages of differentiation, in chicken cardiac cells in culture. Proc Natl Acad Sci U S A. 1982;79:7768–7772. PubMed PMC

Ridge KD, Palczewski K. Visual rhodopsin sees the light: structure and mechanism of G protein signaling. J Biol Chem. 2007;282:9297–9301. PubMed

Rudajev V, Novotný J, Hejnová L, Milligan G, Svoboda P. Dominant portion of thyrotropin-releasing hormone receptor is excluded from lipid domains. Detergent-resistant and detergent-sensitive pools of TRH receptor and Gqalpha/G11alpha protein. J Biochem. 2005;138:111–125. PubMed

Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol. 2000;1:31–39. PubMed

Smith SM, Lei Y, Liu J, Cahill ME, Hagen GM, Barisas BG, Roess DA. Luteinizing hormone receptors translocate to plasma membrane microdomains after binding of human chorionic gonadotropin. Endocrinology. 2006;147:1789–1795. PubMed

Svennerholm L, Bostrom K, Jungbjer B, Olsson L. Membrane lipids of adult human brain: lipid composition of frontal and temporal lobe in subjects of age 20 to 100 years. J Neurochem. 1994;63:1802–1811. PubMed

Tuček S, Musílková J, Nedoma J, Proška J, Shelkovnikov S, Vorlicek J. Positive cooperativity in the binding of alcuronium and N-methylscopolamine to muscarinic acetylcholine receptors. Mol Pharmacol. 1990;38:674–680. PubMed

Vogel WK, Mosser VA, Bulseco DA, Schimerlik MI. Porcine m2 muscarinic acetylcholine receptor-effector coupling in Chinese hamster ovary cells. J Biol Chem. 1995;270:15485–15493. PubMed

Whorton MR, Bokoch MP, Rasmussen SG, Huang B, Zare RN, Kobilka B, Sunahara RK. A monomeric G protein-coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein. Proc Natl Acad Sci U S A. 2007;104:7682–7687. PubMed PMC

Wilkinson M, Siauw M, Horackova M. Modulation of cardiac M2 muscarinic receptor binding by progesterone-related steroids. J Mol Cell Cardiol. 1995;27:1831–1839. PubMed

Cholesterol-dependent amyloid β production: space for multifarious interactions between amyloid precursor protein, secretases, and cholesterol

Allosteric Modulation of Muscarinic Receptors by Cholesterol, Neurosteroids and Neuroactive Steroids

Allosteric Modulation of GPCRs of Class A by Cholesterol

Current Advances in Allosteric Modulation of Muscarinic Receptors

Membrane cholesterol access into a G-protein-coupled receptor

Changes in Membrane Cholesterol Differentially Influence Preferential and Non-preferential Signaling of the M1 and M3 Muscarinic Acetylcholine Receptors

Subtype differences in pre-coupling of muscarinic acetylcholine receptors